The FLEX Study demonstrates the prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2- early-stage breast cancer
STUDY FINDINGS
- In this Real World Evidence (RWE) prospective, propensity score matched study of 1002 patients, those with increasing MammaPrint Index risk (High Risk) had significantly lower risk of Distant Recurrence Free Interval (DRFI) events when treated with ET+CT (endocrine therapy+chemotherapy) compared to ET alone.
- These RWD confirm MammaPrint’s comprehensive utility, as prognostic of recurrence risk and predictive of CT benefit for patients with HR+HER2- early-stage breast cancer.
- Consistent with findings from MINDACT, patients with MammaPrint indices within Low and UltraLow Risk ranges did not derive significant CT benefit.
- Chemotherapy benefit is not predicted by higher tumor grade after adjusting for MammaPrint Index and clinical factors. Observed CT benefit in premenopausal patients with MammaPrint Low Risk tumors may be due to ovarian function suppression (Whitworth et al. Ann Surg Oncol. 2022)
Dive deeper into the data with our Medical team
Request Data Review / Additional Data:
